Buckhead Capital Management LLC Has $1.23 Million Stake in Eli Lilly and Company (NYSE:LLY)

Buckhead Capital Management LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 0.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,104 shares of the company’s stock after acquiring an additional 15 shares during the period. Buckhead Capital Management LLC’s holdings in Eli Lilly and Company were worth $1,226,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Vicus Capital raised its stake in Eli Lilly and Company by 78.6% during the third quarter. Vicus Capital now owns 977 shares of the company’s stock worth $525,000 after acquiring an additional 430 shares in the last quarter. Callahan Advisors LLC raised its stake in Eli Lilly and Company by 655.2% during the third quarter. Callahan Advisors LLC now owns 7,779 shares of the company’s stock worth $4,178,000 after acquiring an additional 6,749 shares in the last quarter. Live Oak Private Wealth LLC raised its stake in Eli Lilly and Company by 2.3% during the third quarter. Live Oak Private Wealth LLC now owns 1,809 shares of the company’s stock worth $972,000 after acquiring an additional 40 shares in the last quarter. Kingswood Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 102.9% during the third quarter. Kingswood Wealth Advisors LLC now owns 3,907 shares of the company’s stock worth $2,099,000 after purchasing an additional 1,981 shares during the last quarter. Finally, Xponance Inc. grew its holdings in shares of Eli Lilly and Company by 0.3% during the third quarter. Xponance Inc. now owns 189,291 shares of the company’s stock worth $101,674,000 after purchasing an additional 590 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.6 %

Shares of LLY stock traded down $4.35 during trading hours on Wednesday, reaching $776.75. The company had a trading volume of 2,762,706 shares, compared to its average volume of 3,067,439. Eli Lilly and Company has a 12 month low of $399.26 and a 12 month high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The business has a fifty day simple moving average of $761.41 and a 200-day simple moving average of $669.21. The company has a market cap of $738.04 billion, a price-to-earnings ratio of 133.47, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the company earned $1.62 earnings per share. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on LLY shares. Morgan Stanley increased their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Truist Financial raised their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a report on Wednesday. BMO Capital Markets raised their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $742.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.